HRP20190815T1 - Piridonski derivati korišteni kao inhibitori kinaze reorganizirane tijekom transfekcije (ret) - Google Patents

Piridonski derivati korišteni kao inhibitori kinaze reorganizirane tijekom transfekcije (ret) Download PDF

Info

Publication number
HRP20190815T1
HRP20190815T1 HRP20190815TT HRP20190815T HRP20190815T1 HR P20190815 T1 HRP20190815 T1 HR P20190815T1 HR P20190815T T HRP20190815T T HR P20190815TT HR P20190815 T HRP20190815 T HR P20190815T HR P20190815 T1 HRP20190815 T1 HR P20190815T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
salt
disease
Prior art date
Application number
HRP20190815TT
Other languages
English (en)
Croatian (hr)
Inventor
Michael P. Demartino
Huiping Amy Guan
Original Assignee
Glaxosmithkline Intellectual Property Development Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property Development Limited filed Critical Glaxosmithkline Intellectual Property Development Limited
Publication of HRP20190815T1 publication Critical patent/HRP20190815T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
HRP20190815TT 2014-09-10 2015-09-09 Piridonski derivati korišteni kao inhibitori kinaze reorganizirane tijekom transfekcije (ret) HRP20190815T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2014086197 2014-09-10
CN2015086995 2015-08-14
EP15767599.2A EP3191450B1 (en) 2014-09-10 2015-09-09 Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors
PCT/IB2015/056905 WO2016038552A1 (en) 2014-09-10 2015-09-09 Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors

Publications (1)

Publication Number Publication Date
HRP20190815T1 true HRP20190815T1 (hr) 2019-07-12

Family

ID=54186249

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190815TT HRP20190815T1 (hr) 2014-09-10 2015-09-09 Piridonski derivati korišteni kao inhibitori kinaze reorganizirane tijekom transfekcije (ret)

Country Status (36)

Country Link
US (4) US9918974B2 (2)
EP (2) EP3517526B1 (2)
JP (2) JP6538154B2 (2)
KR (1) KR20170045350A (2)
CN (1) CN107074768B (2)
AU (1) AU2015313841B2 (2)
BR (1) BR112017004900A2 (2)
CA (1) CA2960768A1 (2)
CL (1) CL2017000588A1 (2)
CO (1) CO2017002273A2 (2)
CR (1) CR20170093A (2)
CY (1) CY1121661T1 (2)
DK (1) DK3191450T3 (2)
DO (1) DOP2017000059A (2)
EA (1) EA033544B1 (2)
ES (2) ES2816453T3 (2)
HR (1) HRP20190815T1 (2)
HU (1) HUE044604T2 (2)
IL (1) IL250908B (2)
LT (1) LT3191450T (2)
MA (1) MA40581A (2)
ME (1) ME03432B (2)
MX (1) MX373863B (2)
MY (1) MY181913A (2)
PE (1) PE20170705A1 (2)
PH (1) PH12017500425A1 (2)
PL (1) PL3191450T3 (2)
PT (1) PT3191450T (2)
RS (1) RS58813B1 (2)
SG (1) SG11201701694QA (2)
SI (1) SI3191450T1 (2)
SM (1) SMT201900304T1 (2)
TW (1) TWI683807B (2)
UA (1) UA122213C2 (2)
UY (1) UY36293A (2)
WO (1) WO2016038552A1 (2)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ604708A (en) 2010-05-20 2015-05-29 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
PE20170705A1 (es) 2014-09-10 2017-05-21 Glaxosmithkline Ip Dev Ltd Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
EA032030B1 (ru) 2014-09-10 2019-03-29 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Соединения в качестве ингибиторов реаранжированной во время трансфекции (ret) киназы
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
BR112018000808A2 (pt) 2015-07-16 2018-09-04 Array Biopharma Inc compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
PL3371171T3 (pl) 2015-11-02 2024-03-25 Blueprint Medicines Corporation Inhibitory RET
TW201738228A (zh) 2016-03-17 2017-11-01 藍圖醫藥公司 Ｒｅｔ之抑制劑
US10227329B2 (en) 2016-07-22 2019-03-12 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
JP2020519672A (ja) 2017-05-15 2020-07-02 ブループリント メディシンズ コーポレイション ＲＥＴ阻害剤とｍＴＯＲＣ１阻害剤との組合せ及び異常なＲＥＴ活性によって媒介されるがんを処置するためのその使用
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
SI3773589T1 (sl) 2018-04-03 2024-03-29 Blueprint Medicines Corporation Inhibitor RET za uporabo pri zdravljenju raka, ki ima RET spremembo
EP3849986B1 (en) 2018-09-10 2022-06-08 Array Biopharma, Inc. Fused heterocyclic compounds as ret kinase inhibitors
JP2023527412A (ja) 2020-05-29 2023-06-28 ブループリント メディシンズ コーポレイション プラルセチニブの固体形態
CN115803316B (zh) * 2020-07-23 2024-12-06 深圳晶泰科技有限公司 吡啶酮类化合物及其制备方法和应用
KR20250052364A (ko) 2022-08-24 2025-04-18 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120046290A1 (en) 1997-12-22 2012-02-23 Jacques Dumas Inhibition of p38 kinase activity using substituted heterocyclic ureas
US20070244120A1 (en) 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
SK286213B6 (sk) * 1997-12-22 2008-05-06 Bayer Corporation Substituované heterocyklické močoviny, farmaceutický prípravok ich obsahujúci a ich použitie
MXPA00006233A (es) 1997-12-22 2002-09-18 Bayer Ag Inhibicion de la actividad de la cinasa p38 utilizando ureas heterociclicas sustituidas.
KR20020060160A (ko) 1999-08-12 2002-07-16 파마시아 이탈리아 에스.피.에이. 3(5)-아미노-피라졸 유도체, 이의 제조 방법 및항종양제로서의 이의 용도
AU2002215053A1 (en) * 2000-11-27 2002-06-24 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
DE10201764A1 (de) 2002-01-18 2003-07-31 Bayer Cropscience Ag Substituierte 4-Aminopyridin-Derivate
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
AU2003264386A1 (en) 2002-09-10 2004-04-30 Kyorin Pharmaceutical Co., Ltd. 4-(substituted aryl)-5-hydroxyisoquinolinone derivative
CA2536293A1 (en) 2003-08-22 2005-03-03 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating copd and pulmonary hypertension
TW200530236A (en) * 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
BRPI0519424B8 (pt) * 2004-12-28 2021-05-25 Athenex Inc compostos, composição e uso dos ditos compostos para a preparação de um medicamento para prevenção ou tratamento de um distúrbio de proliferação celular ou infecção microbiana
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
GB0507575D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds
US8247556B2 (en) * 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
TW200804349A (en) * 2005-12-23 2008-01-16 Kalypsys Inc Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases
WO2008002676A2 (en) 2006-06-29 2008-01-03 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
KR101507375B1 (ko) * 2006-09-15 2015-04-07 엑스커버리 홀딩 컴퍼니 엘엘씨 키나아제 억제제 화합물
CA2666116A1 (en) 2006-10-16 2008-04-24 Novartis Ag Phenylacetamides useful as protein kinase inhibitors
DK2848610T3 (da) * 2006-11-15 2017-11-06 Ym Biosciences Australia Pty Hæmmere af kinaseaktivitet
JP2013502429A (ja) 2009-08-19 2013-01-24 アムビト ビオスシエンセス コルポラチオン ビアリール化合物及びその使用方法
US9073895B2 (en) 2010-12-16 2015-07-07 Boehringer Ingelheim International Gmbh Biarylamide inhibitors of leukotriene production
BR112015023618A2 (pt) 2013-03-15 2017-07-18 Glaxosmithkline Ip Dev Ltd derivados de piridina como inibidores de quinase reorganizada durante a transfecção (ret)
MA38394B1 (fr) 2013-03-15 2018-04-30 Glaxosmithkline Ip Dev Ltd Dérivés pyridine utilisés comme inhibiteurs de la kinase réarrangée au cours de la transfection (ret)
EA032030B1 (ru) 2014-09-10 2019-03-29 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Соединения в качестве ингибиторов реаранжированной во время трансфекции (ret) киназы
PE20170705A1 (es) * 2014-09-10 2017-05-21 Glaxosmithkline Ip Dev Ltd Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)

Also Published As

Publication number Publication date
IL250908B (en) 2020-11-30
EP3517526A1 (en) 2019-07-31
SI3191450T1 (sl) 2019-07-31
BR112017004900A2 (pt) 2017-12-12
TWI683807B (zh) 2020-02-01
PH12017500425B1 (en) 2017-07-31
JP2019163316A (ja) 2019-09-26
JP6728447B2 (ja) 2020-07-22
US20190247382A1 (en) 2019-08-15
CY1121661T1 (el) 2020-07-31
DOP2017000059A (es) 2017-03-31
EP3517526B1 (en) 2020-08-19
EP3191450B1 (en) 2019-04-10
US20170340617A1 (en) 2017-11-30
DK3191450T3 (da) 2019-05-20
CR20170093A (es) 2017-07-17
KR20170045350A (ko) 2017-04-26
MX373863B (es) 2020-03-26
US10292975B2 (en) 2019-05-21
UA122213C2 (uk) 2020-10-12
US20190022078A1 (en) 2019-01-24
MA40581A (fr) 2019-04-10
EP3191450A1 (en) 2017-07-19
HUE044604T2 (hu) 2019-11-28
RS58813B1 (sr) 2019-07-31
AU2015313841B2 (en) 2018-03-08
SMT201900304T1 (it) 2019-07-11
LT3191450T (lt) 2019-06-10
AU2015313841A1 (en) 2017-03-23
ES2725704T3 (es) 2019-09-26
US10111866B2 (en) 2018-10-30
EA033544B1 (ru) 2019-10-31
PH12017500425A1 (en) 2017-07-31
CL2017000588A1 (es) 2017-10-06
CN107074768A (zh) 2017-08-18
PE20170705A1 (es) 2017-05-21
US10709695B2 (en) 2020-07-14
US20180147194A1 (en) 2018-05-31
MX2017003114A (es) 2017-11-15
EA201790546A1 (ru) 2017-07-31
JP6538154B2 (ja) 2019-07-03
US9918974B2 (en) 2018-03-20
TW201625534A (en) 2016-07-16
CN107074768B (zh) 2019-12-10
IL250908A0 (en) 2017-04-30
UY36293A (es) 2016-04-01
SG11201701694QA (en) 2017-04-27
CO2017002273A2 (es) 2017-06-20
JP2017527578A (ja) 2017-09-21
ES2816453T3 (es) 2021-04-05
CA2960768A1 (en) 2016-03-17
PT3191450T (pt) 2019-05-29
MY181913A (en) 2021-01-14
ME03432B (me) 2020-01-20
PL3191450T3 (pl) 2019-08-30
WO2016038552A1 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
HRP20190815T1 (hr) Piridonski derivati korišteni kao inhibitori kinaze reorganizirane tijekom transfekcije (ret)
JP2017527578A5 (2)
HRP20210928T1 (hr) Soli ili ko-kristali 3- (3-dimetilamino-1-etil-2-metil-propil)-fenola
HRP20241768T1 (hr) Heterociklički spoj
HRP20170638T1 (hr) MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI
HRP20170363T1 (hr) Derivati piridina kao inhibitori kinaze pregrađene prilikom transfekcije (ret)
SI2989100T1 (en) NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6
JP2013543896A5 (2)
HRP20210957T1 (hr) Spojevi inhibitori autotaksina
HRP20150531T1 (hr) Pirazolilaminopiridini kao inhibitori fak
HRP20210681T1 (hr) Kristalne soli (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroizokinolin-2(1h)-il)-2-hidroksipropil)pirimidin-4-karboksamida
RU2017111590A (ru) Кристаллические формы 2-(4-(4-этокси-6-оксо-1,6-дигидропиридин-3-ил)-2-фторфенил)-n-(5-(1,1,1-трифтор-2- метилпропан-2-ил)изоксазол-3-ил)ацетамида
EA201491671A1 (ru) Гетероциклильные соединения
HRP20191979T1 (hr) Heteoarilni spojevi koji su korisni kao inhibitori sumo-aktivirajućeg enzima
MX348548B (es) Derivado heterociclico y farmaceutico.
EA201400553A1 (ru) Производные 2-(1,2,3-триазол-2-ил)бензамида и 3-(1,2,3-триазол-2-ил)пиколинамида
JP2015524472A5 (2)
NZ701702A (en) Carbazole-containing sulfonamides as cryptochrome modulators
JP2014062126A5 (2)
EA201300436A1 (ru) Совместные кристаллы и соли ингибиторов ccr3
ME03723B (me) 2-amin0-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridini kао васе1 inhibiтori
HRP20171515T1 (hr) Spojevi fenoksietilpiperidina
EA201591684A1 (ru) Кристаллические формы ингибиторов тирозинкиназы и их солей
BR112015016184A2 (pt) derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral
HRP20210158T1 (hr) Postupak i sustav za premještanje fluida iz posude za opskrbu u komponentu za isporuku